Glynase

Glycemic Control, Type 2 Diabetes, Gestational Diabetes Mellitus
Treatment
3 FDA approvals
20 Active Studies for Glynase

What is Glynase

GlyburideThe Generic name of this drug
Treatment SummaryGlyburide is a type of drug used to treat people with type 2 diabetes. It is usually given to people who cannot control their diabetes with the usual first-line therapy, which is metformin. Glyburide works by increasing the amount of insulin in the body, which helps to regulate blood sugar levels. It was FDA approved in 1984 and a combination of glyburide and metformin was approved in 2000.
Micronaseis the brand name
image of different drug pills on a surface
Glynase Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Micronase
Glyburide
1984
341

Approved as Treatment by the FDA

Glyburide, also known as Micronase, is approved by the FDA for 3 uses which include Type 2 Diabetes Mellitus and Type 2 Diabetes .
Type 2 Diabetes Mellitus
Helps manage Type 2 Diabetes Mellitus
Type 2 Diabetes
Helps manage Type 2 Diabetes Mellitus
Glycemic Control
Used to treat Glycemic Control in combination with Metformin

Effectiveness

How Glynase Affects PatientsGlyburide is a drug that helps the body produce insulin. It is taken once daily and the dose is usually started low (0.75mg) and can increase up to 10mg or more as needed. It is important to note that taking glyburide may increase the risk of cardiovascular death, similar to the drug tolbutamide.
How Glynase works in the bodyGlyburide is a type of drug that helps the body make and release more insulin. It does this by blocking potassium channels, which normally open in response to high glucose concentrations and cause the body to make insulin. By forcing them to stay closed, glyburide boosts insulin production.

When to interrupt dosage

The suggested dose of Glynase is contingent upon the determined condition, including Glycemic Control, Type 2 Diabetes and Gestational Diabetes. The measure of dosage fluctuates as per the technique of delivery (e.g. Oral or Tablet) specified in the table below.
Condition
Dosage
Administration
Type 2 Diabetes
, 1.25 mg, 2.5 mg, 1.5 mg, 3.0 mg, 6.0 mg, 5.0 mg, 6.0 mg/mL, 0.6 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral
Gestational Diabetes Mellitus
, 1.25 mg, 2.5 mg, 1.5 mg, 3.0 mg, 6.0 mg, 5.0 mg, 6.0 mg/mL, 0.6 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral
Glycemic Control
, 1.25 mg, 2.5 mg, 1.5 mg, 3.0 mg, 6.0 mg, 5.0 mg, 6.0 mg/mL, 0.6 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral

Warnings

Glynase has six recognized contraindications and should not be taken with any of the conditions given in the below table.Glynase Contraindications
Condition
Risk Level
Notes
Type 1 Diabetes
Do Not Combine
Acidosis
Do Not Combine
Comatose
Do Not Combine
Diabetic Ketoacidosis
Do Not Combine
Pulse Frequency
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Glyburide may interact with Pulse Frequency
There are 20 known major drug interactions with Glynase.
Common Glynase Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be decreased when combined with Glyburide.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Glyburide.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Glyburide.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Glyburide.
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Glyburide.
Glynase Toxicity & Overdose RiskThe lowest toxic dose of the drug in rats has been found to be greater than 3200mg/kg, in mice greater than 1500mg/kg, in rabbits greater than 10,000mg/kg, and in guinea pigs greater than 1500mg/kg. An overdose of this drug can cause low blood sugar levels. Mild hypoglycemia should be treated with sugar and changes to the drug dosage or meal schedule. Severe hypoglycemia can cause coma, seizures, and brain damage and should be treated immediately in a hospital with intravenous sugar and monitored for 24-48 hours.
image of a doctor in a lab doing drug, clinical research

Glynase Novel Uses: Which Conditions Have a Clinical Trial Featuring Glynase?

An array of 196 active trials are being conducted to assess the potential of Glynase in providing Gestational Diabetes, Glycemic Control and Type 2 Diabetes relief.
Condition
Clinical Trials
Trial Phases
Type 2 Diabetes
165 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1
Gestational Diabetes Mellitus
27 Actively Recruiting
Not Applicable, Phase 4, Phase 3, Early Phase 1
Glycemic Control
4 Actively Recruiting
Not Applicable

Glynase Reviews: What are patients saying about Glynase?

5Patient Review
9/16/2009
Glynase for Type 2 Diabetes Mellitus
Glynase has been by far the most effective medication I've tried for my hyperglycemia. Not only did it show results immediately, but over time as I lost weight and exercised more, I was able to reduce my dosage with no loss in efficacy. Additionally, it's very easy to take and I experienced no negative side effects whatsoever.
4Patient Review
2/4/2008
Glynase for Type 2 Diabetes Mellitus
4Patient Review
1/28/2009
Glynase for Type 2 Diabetes Mellitus
3.3Patient Review
10/18/2010
Glynase for Type 2 Diabetes Mellitus
I've been using this medication for about ten years now and it's always been pretty straightforward for me.
3Patient Review
3/16/2010
Glynase for Osteoporosis
This treatment really helped me. I'm grateful for modern medicine.

Patient Q&A Section about glynase

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the generic name for glynase?

"It works by stimulating the release of insulin from the pancreas, leading to better blood sugar control.

Glipizide is a generic drug prescribed to people with type 2 diabetes in order to help control their blood sugar levels. It works by stimulating the release of insulin from the pancreas, which helps to regulate blood sugar levels in the body."

Answered by AI

What is glynase-MF?

"This medicine is a combination of two medicines, Glipizide and Metformin, which is used to treat type 2 diabetes mellitus (DM). It improves blood glucose levels in adults when taken along with a proper diet and regular exercise."

Answered by AI

When should glynase be taken?

"You should take Glynase Tablet before meals, or exactly as your doctor tells you to. There is evidence suggesting that taking Glynase Tablet 30 minutes before breakfast helps control post-meal high blood sugar levels."

Answered by AI

What is the use of glynase?

"Glyburide is a medication used to help control high blood sugar. It is typically used in conjunction with a proper diet and exercise program, and may also be used with other diabetes medications. Managing blood sugar levels can help to prevent a range of complications associated with diabetes, such as kidney damage, blindness, nerve problems, and loss of limb function."

Answered by AI

Clinical Trials for Glynase

Image of University of California, Los Angeles in Los Angeles, United States.

Tailored DPP for Prediabetes

17 - 25
All Sexes
Los Angeles, CA
The goal of this study is to enhance reach and uptake of diabetes prevention among young adults, with a focus on recruiting underserved and high-need students who face additional challenges, including food and financial insecurity. The specific aims are: Aim 1 - Evaluate the efficacy of an AYA-tailored version of the UC DPP for mitigating type 2 diabetes risk (i.e., weight change) in a pre/post pilot trial. The investigators hypothesize that the AYA-tailored intervention will be effective at producing 5% weight loss from baseline to program completion (at 9-months). Aim 2 - Assess the feasibility and acceptability of an AYA-tailored version of the UC DPP program. The investigators hypothesize that it will be feasible to recruit the desired number of participants given proposed innovative outreach strategies, and that the AYA-tailored intervention will be deemed acceptable to participants both qualitatively and in regards to their retention in the program at rates similar to the larger UC DPP. The investigators will recruit 80 UCLA undergraduate students. Participants will be asked to complete a brief screening online form to assess eligibility and to collect contact information. The PI and/or Research Assistants (RAs) will reach out to eligible participants to obtain informed consent and enroll them in the pilot trial. The investigators will randomize participants to the tailored DPP cohort vs control cohort. Control participants will be offered the opportunity to participate in the tailored DPP in the following academic year. The tailored DPP intervention will be online and asynchronously. Participants will be asked to complete the intervention lessons on their own time. Each lesson typically takes on average 15 minutes to complete. Control group will receive each intervention materials via e-mail for participants to review on their own time and will receive acceptability surveys. The interventions for the control group will be remote. A research assistant will meet with control participants via Zoom to explain the intervention materials. Control group will receive access to a study habits intervention, alcohol use intervention, and financial literacy intervention. At the end of each quarter (Fall, Winter, and Spring), both control and intervention participants will receive an email with a unique link to a brief REDCap survey to ascertain acceptability of sessions/lessons. Furthermore, participants will complete baseline and 9-month follow-up assessments. Participants will complete a 30 minute questionnaire and height/weight measurements will be collected by a RA. Participants will be asked to self-report weight and physical activity at the end of the fall and winter quarter; data will be collected via brief REDCap survey.
Recruiting
Has No Placebo
University of California, Los AngelesLauren E Wisk, PhD
Image of Medpace Clinical Pharmaology Unit in Cincinnati, United States.

PATAS for Type 2 Diabetes

18 - 55
All Sexes
Cincinnati, OH
The primary objective of Part 1 of this study is to evaluate safety and tolerability of single subcutaneous (SC) doses of PATAS in healthy subjects. The secondary objective of Part 1 of this study is to determine the pharmacokinetics (PK) of single SC doses of PATAS in healthy subjects. The primary objectives of Part 2 of this study are to evaluate the safety and tolerability of 4 weekly SC doses of PATAS in subjects with T2D; and to determine the PK and pharmacodynamics (PD) of 4 weekly SC doses of PATAS in subjects with T2D. The secondary objectives of Part 2 of this study are to evaluate the potential effect of multiple SC doses of PATAS on markers of glycemic control, as measured by glucose levels, insulin levels, and other metabolomic biomarkers; and to characterize the adverse event (AE) profiles of the various dose levels of PATAS.
Phase 1
Waitlist Available
Medpace Clinical Pharmaology UnitVincent Marion, Ph.D.AdipoPharma LLC
Have you considered Glynase clinical trials? We made a collection of clinical trials featuring Glynase, we think they might fit your search criteria.Go to Trials
Have you considered Glynase clinical trials? We made a collection of clinical trials featuring Glynase, we think they might fit your search criteria.Go to Trials
Image of Exercise Metabolism and Inflammation Laboratory in Okanagan, Canada.

Aerobic Exercise with Blood Flow Restriction for Type 2 Diabetes

19 - 64
All Sexes
Okanagan, Canada
The goal of this trial is to learn if blood flow restriction training with treadmill walking is possible for individuals living with type 2 diabetes. It will also learn about how the blood flow restriction with treadmill walking could improve health. The main questions it aims to answer are: Is 6 weeks of treadmill walking with blood flow restriction reasonable for people with type 2 diabetes to perform? Does treadmill walking with blood flow restriction training help manage type 2 diabetes better than just treadmill walking? Researchers will compare treadmill walking with blood flow restriction to treadmill walking without blood flow restriction to see if blood flow restriction works to manage type 2 diabetes based on fitness and blood sugar levels. Participants will: Perform treadmill walking with or without blood flow restriction for 96 minutes a week for 6 weeks. Visit the lab before and after the exercise for tests and questionnaires.
Waitlist Available
Has No Placebo
Exercise Metabolism and Inflammation Laboratory (+2 Sites)Martin Senechal, PhD
Image of Jefferson Health New Jersey in Sewell, United States.

Continuous vs Finger-stick Glucose Monitoring for Type 2 Diabetes in Pregnancy

18+
Female
Sewell, NJ
The purpose of this study is to compare patient adherence to blood sugar monitoring during pregnancy using two different measurement methods in pregnancies complicated by pregestational type 2 diabetes (T2DM). Pregnant patients with T2DM are at risk of having larger babies, babies with low sugar levels in the first 24 hours of life, higher rates of cesarean delivery, stillbirth (death of baby inside the womb), and hypertensive or high blood pressure disorders of pregnancy, such as preeclampsia. Prior studies have shown that treating high blood sugars in pregnancy with medications can reduce these risks. To determine the amount of medication needed, recording of blood sugar levels is necessary. This trial aims to determine whether continuous blood sugar monitors have improved patient recording of blood sugar levels over finger stick blood sugar measurements. Patients involved in the study will be assigned to either: 1. Fingerstick glucose monitoring (FSG) 2. Continuous glucose monitoring (CGM) Patients will be randomize in a 1:1 ratio. FSG Group: blood sugar is tested four times daily - once fasting and two hours after every meal (post-prandial). Blood will be tested using a glucometer, and values will be recorded in a blood sugar log from the time of enrollment to the time of delivery. CGM Group: A CGM sensor will be placed on the patient's arm for blood sugar collection every 3-5 minutes. This data is sent to a phone application from the time of enrollment to the time of delivery. These sensors will need to be replaced every 14 days. Percent adherence will be recorded from the time you were randomized to a study group until delivery.
Recruiting
Has No Placebo
Jefferson Health New Jersey (+1 Sites)
Image of McMaster University in Hamilton, Canada.

Health Coaching for Type 2 Diabetes and Mental Health

18+
All Sexes
Hamilton, Canada
Managing both type 2 diabetes and mental health challenges can be difficult, and many people do not receive care that supports both. This study looks at how virtual health coaching and support from interdisciplinary care teams can help people better manage their health. The purpose of this study is to test the effectiveness of a virtual health coaching program for adults living with type 2 diabetes and mental health challenges compared to usual care. The Technology-Enabled Collaborative Care for type 2 Diabetes and Mental health (TECC-DM) program includes weekly coaching calls, support from an interdisciplinary care team, and online tools to aid self-management. The findings from this study will be used to help improve services for people who have type 2 diabetes and co-occurring mental health symptoms.
Waitlist Available
Has No Placebo
McMaster UniversityCarly Whitmore, RN PhD
Have you considered Glynase clinical trials? We made a collection of clinical trials featuring Glynase, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security